BioCorRx’s “Beat Addiction Recovery Program” therapy modules will be the central addiction treatment resource offered in Phase I of 2B3D’s VRME launch in January, 2023
Los Angeles, CA, Sept. 29, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – 2B3D, a military veteran-operated mental health technology solutions firm specializing in VR, Gaming, NFTs, developing metaverse solutions for PTSD and addiction treatment, today announced the scope of deliverables from its addiction treatment partner, BioCorRx.
BioCorRx is a best-in-class addiction treatment firm that leverages a holistic mix of cognitive behavior therapy in conjunction with lifestyle modifications and medication where appropriate as prescribed by a physician for treatment of a wide array of substance use disorders. In 2B3D’s beta platform launch, coming in Q1 2023, BioCorRx will contribute digital resources from its catalog of signature behavior modification modules, which will be discoverable in the metaverse environment by the avatars of platform users.
2B3D’s end-to-end prototype for live, free PTSD treatment for military veterans allows platform users to self-identify addiction issues upon first arrival in the VR Medical Environment (VRME). Where an addiction issue is present in someone suffering from PTSD, VRx treatment for PTSD can still be initiated; but to ensure best results, addiction treatment resources and protocols should be deployed as early as possible in the process.
BioCorRx’s course modules are a popular and well-tested component of the firm’s “Beat Addiction Recovery Program,” a non-metaverse treatment therapy that is largely app-driven. Vistors to 2B3D’s Phase I environment will be able to discover course modules as NFTs, and engage with them while in the VR experience, as well as offline in other environments at their convenience.
“We are thrilled with the inclusion of select resources from BioCorRx’s therapy curriculum in our Phase I VRME,” said Robert Bell, CEO of 2B3D. “A CBT-forward, holistic approach is at the core of modern thinking when it comes to a lot of categories of behavior and lifestyle modification, and BioCorRx has been working this way for years in the addiction treatment space. There’s no doubt in my mind that visitors to our VRME who need it will get tremendous value out of these BioCorRx resources which will be discoverable as NFTs.”
Nascent addiction treatment protocols—replete with components that reflect recent trends, such as reward incentives and gamification—are more needed than ever, as the US is currently losing a titanic battle to both fentanyl and methamphetamines. While similar to morphine, fentanyl is 50 to 100 times more potent, according to an article from the National Institute of Health. The primary reason for this massive increase in potency is due to opioid resistant pain, easy access to illegal opioids, over prescription, and the intensely pleasurable, dreamlike euphoria that opioids cause when overused. In 2017, 59 percent of opioid-related deaths involved fentanyl, just over four times as many as the 14 percent of opioid-related deaths in 2010.
Visit 2B3D.com for more info on its beta platform launch in January, and info on its upcoming NFT drop this October.
Virtual reality succeeds where video conference calls fail. In 2B3D’s metaverse, military veterans will be able to reach out to mental health professionals using a customized avatar for more personalized online interactions. 2B3D is developing VRx to be more than just a portal to access VR therapy. This is where veterans can rally, regroup, play games, and spend time with friends and family, no matter where they are in the world.
BioCorRx Inc. is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Beat Addiction Recovery is a substance use disorder recovery program that typically includes BioCorRx’s proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx® Weight Loss Program is also a medication assisted weight loss program that includes access to concierge on-demand wellness specialists: nutritionists, fitness experts and personal support from behavioral experts; please visit www.uncraverx.com for more information on UnCraveRx®. The Company also controls BioCorRx Pharmaceuticals, a clinical stage drug development subsidiary currently seeking FDA approval for BICX104, an implantable naltrexone pellet for treatment of alcohol and opioid use disorders. For more information on BICX and its subsidiary pipeline, please visit www.BioCorRx.com.
The Food and Drug Administration granted Amylyx Pharmaceuticals a hard-won approval in ALS treatment, but AMLX stock sank Friday.
Intercept Pharmaceuticals' experimental NASH treatment failed in patients with liver cirrhosis, leading ICPT stock to plummet Friday.
In the past two years, biotech companies Moderna (NASDAQ: MRNA) and Novavax (NASDAQ: NVAX) rose to fame thanks to their successful attempts to develop vaccines for COVID-19 and help us end the outbreak. The pandemic isn't over yet, but Moderna and Novavax have given up substantial chunks of their value in the past year. Where does that leave Moderna and Novavax?
The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.
Horizon (HZNP) completes enrollment in the phase IV study evaluating Tepezza for the treatment of thyroid eye disease in patients with a low clinical activity score.
Biohaven Pharmaceutical said Thursday its experimental ALS treatment failed in a midstage study, leading BHVN stock to dip slightly.
Amylyx Pharmaceuticals Inc. has won its first approval from the U.S. Food and Drug Administration for a drug designed to treat amyotrophic lateral sclerosis, or ALS.
Vas Narasimhan, CEO of Novartis, talks about the Big Pharma company's new focus on the U.S. market—and why he believes investors are undervaluing its potential.
Biogen stock catapulted Wednesday — bringing shares of other Alzheimer's plays with it — after its experimental treatment succeeded in a test.
Regulatory and pipeline updates from BIIB and IONS are the key highlights from the biotech sector during the past week.
Sparrow spokesperson Corey Alexander confirmed the layoffs and said cuts would target leadership and non-patient care roles.
For years health equity advocates have pointed to the role that food insecurity, among other factors like housing and job, plays in poorer health outcomes in the country. The White House's first conference in 50 years addressing hunger could be a first step by the nation's highest office in addressing the impact of food on health. That, at least, is the belief of one company which participated at the event Wednesday.
Despite the macroeconomic challenges, rising dependence on telehealth and the dominance of AI are likely to drive the Zacks Medical – Outpatient and Home Healthcare industry. AMED, ADUS and HNGR are well poised to gain from the prospects.
"It taught me a valuable lesson I have never forgotten."View Entire Post ›
The medicine, called Relyvrio, gives patients with the degenerative disease a new treatment option, but some FDA staff questioned its effectiveness.
Despite a lack of data, anti-trans proponents often center narratives of regret to dissuade gender-affirming health care.
The Food and Drug Administration on Thursday approved a new drug to slow the progression of ALS, a fatal neurodegenerative disease for which there is no cure.
Clear evidence this week that Eisai and Biogen's drug lecanemab slows cognitive decline in early stage dementia has galvanized efforts among Alzheimer's researchers toward a tantalizing goal – preventing dementia even before symptoms start. Lecanemab is an antibody that targets and removes toxic clumps of a protein called amyloid beta that accumulate in the brains of patients with Alzheimer's. Results from the companies' 1,800-patient trial released on Tuesday showed convincingly that doing so also slows the advance of the mind-robbing disease. In volunteers with mild cognitive impairment and early stage dementia, the drug showed a 27% reduction in cognitive decline after 18 months compared with those who got a placebo.
A new drug aimed at slowing cognitive decline in patients with early Alzheimer’s disease has proved effective in studies.
What is Biden's 'Cancer Moonshot'?